Data from twelve studies [37,38,39,40,41,42,43,44,45,46,47,48] estimating the prevalence of seropositivity for IgA tissue transglutaminase (tTG) in patients with MS do not support an increased prevalence of CD among patients with MS, whereas a single study found higher mean values of IgA-tTG and IgG-tTG among 30 patients with MS compared to 25 HCs [49]. This evidence concerns the gene TGM2 and myeloid sarcoma.